Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last4,581 to 4,600 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Sexual Health-PRO vs Post Visit (Fidelity) Survey: PrEP Prescriptions | 11 of 1,135 0 of 242 | 1.0 points -0.7 to 1.7 | 1,377 | NCT07209722 PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare |
| Selenium vs Placebo: deaths from any cause | 11 of 685 10 of 689 | 0.2 points -1.2 to 1.6 | 1,374 | NCT00078897 Selenium for Prevention of Adenomatous Colorectal Polyps |
| Selenium vs Placebo: serious adverse events | 228 of 685 226 of 689 | 0.5 points -4.5 to 5.4 | 1,374 | NCT00078897 Selenium for Prevention of Adenomatous Colorectal Polyps |
| Group 1: Menactra and Routine Pediatric Vaccines vs Group 2: Routine Pediatric Vaccines: serious adverse events | 42 of 1,053 5 of 321 | 2.4 points 0.2 to 4.1 | 1,374 | NCT00483574 Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers |
| Telmisartan 40mg and Amlodipine 5mg vs Telmisartan 80mg and Amlodipine 5mg: serious adverse events | 22 of 976 6 of 397 | 0.7 points -1.2 to 2.1 | 1,373 | NCT00614380 Open Label Study Telmisartan and Amlodipine in Hypertension |
| Naïve to Botox® Treatment vs Non-naïve to Botox® Treatment: serious adverse events | 5 of 506 33 of 866 | -2.8 points -4.4 to -1.1 | 1,372 | NCT00535938 MDs on Botox Utility (MOBILITY) |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in The Safety Population | 176 of 685 176 of 687 | 0.1 points -4.5 to 4.7 | 1,372 | NCT03788967 Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| TBPM-PI-HBr 600 mg vs Ertapenem 1 g: serious adverse events | 14 of 685 12 of 687 | 0.3 points -1.2 to 1.8 | 1,372 | NCT03788967 Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) |
| Subcutaneous Abatacept vs Intravenous Abatacept: Double-blind Period: Number of Participants Achieving American College of Rheumatology (ACR) 20 Response at Day 169 | 527 of 693 514 of 678 | 0.2 points -4.3 to 4.8 | 1,371 | NCT00559585 Methotrexate-Inadequate Response Study |
| BCG-vaccine vs Control Children: Specific IgE | 55 of 743 50 of 627 | -0.6 points -3.5 to 2.2 | 1,370 | NCT01694108 Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. |
| Indomethacin vs Glycerin: the Incidence of Post-ESWL Pancreatitis | 60 of 685 84 of 685 | -3.5 points -6.8 to -0.2 | 1,370 | NCT02797067 Rectal Indomethacin to Prevent Post ESWL-pancreatitis |
| Restrictive vs Liberal: A Composite Endpoint of All-cause Post-randomization Mortality, Myocardial Infarction (MI), Coronary Revascularization, Acute Renal Failure, or Post-randomization Ischemic Stroke up to 90 Days After Randomization | 71 of 700 61 of 670 | 1.0 points -2.1 to 4.2 | 1,370 | NCT03229941 Transfusion Trigger After Operations in High Cardiac Risk Patients |
| CHICA Type 2 Diabetes Module vs Usual Care: Number of Children With Documented Risk Factors for Type 2 Diabetes | 283 of 685 282 of 684 | 0.1 points -5.1 to 5.3 | 1,369 | NCT01814787 Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes |
| Restrictive vs Liberal: All-cause Mortality at 1 Year After Randomization | 105 of 701 94 of 668 | 0.9 points -2.8 to 4.6 | 1,369 | NCT03229941 Transfusion Trigger After Operations in High Cardiac Risk Patients |
| Restrictive vs Liberal: deaths from any cause | 105 of 701 94 of 668 | 0.9 points -2.8 to 4.6 | 1,369 | NCT03229941 Transfusion Trigger After Operations in High Cardiac Risk Patients |
| LY2605541 + Insulin Lispro vs Insulin Glargine + Insulin Lispro: serious adverse events | 79 of 691 63 of 677 | 2.1 points -1.1 to 5.4 | 1,368 | NCT01468987 A Study in Participants With Type 2 Diabetes Mellitus |
| Alogliptin + Thiazolidinedione vs Alogliptin + Other: serious adverse events | 3 of 1,248 0 of 120 | 0.2 points -2.9 to 0.7 | 1,368 | NCT01945242 Alogliptin Tablets Special Drug Use Surveillance "Type 2 Diabetes Mellitus: Combination Therapy With Thiazolidinediones" |
| Teriparatide vs Risedronate: serious adverse events | 138 of 683 117 of 683 | 3.1 points -1.1 to 7.2 | 1,366 | NCT01709110 VERtebral Fracture Treatment Comparisons in Osteoporotic Women |
| BE1116 vs Placebo: deaths from any cause | 146 of 689 114 of 677 | 4.4 points 0.2 to 8.5 | 1,366 | NCT05568888 Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study ) |
| Intervention vs Control: serious adverse events | 7 of 683 3 of 682 | 0.6 points -0.4 to 1.7 | 1,365 | NCT00667368 Bacterial Vaginosis Home Screening to Prevent STDs |
Code
curl "https://conductscience.org/api/comparisons/v1?page=230"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=230
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT07209722-0939329c",
"title": "Sexual Health-PRO vs Post Visit (Fidelity) Survey: PrEP Prescriptions",
"summary": "11 of 1135 against 0 of 242; risk difference 1.0 points, 95% interval -0.7 to 1.7; NCT07209722, PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare",
"record": "/library/comparisons/NCT07209722-0939329c",
"nct_id": "NCT07209722",
"kind": "outcome",
"participants": 1377,
"risk_difference": {
"value": 0.009691629955947136,
"lower": -0.0065074332379784095,
"upper": 0.017270837089201376
},
"group_1": "11 of 1,135",
"group_2": "0 of 242",
"difference": "1.0 points",
"interval": "-0.7 to 1.7",
"trial_title": "PrEP4Her: Developing a Novel Strategy to Implement PrEP Into Women's Healthcare"
},
{
"id": "NCT00078897-deaths",
"title": "Selenium vs Placebo: deaths from any cause",
"summary": "11 of 685 against 10 of 689; risk difference 0.2 points, 95% interval -1.2 to 1.6; NCT00078897, Selenium for Prevention of Adenomatous Colorectal Polyps",
"record": "/library/comparisons/NCT00078897-deaths",
"nct_id": "NCT00078897",
"kind": "deaths",
"participants": 1374,
"risk_difference": {
"value": 0.0015446060618901827,
"lower": -0.012378097588588337,
"upper": 0.01565530519348074
},
"group_1": "11 of 685",
"group_2": "10 of 689",
"difference": "0.2 points",
"interval": "-1.2 to 1.6",
"trial_title": "Selenium for Prevention of Adenomatous Colorectal Polyps"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=231",
"request_id": "gZLrkcg4zAJf4k7W"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
The conductscience.com catalog
One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.
Open Targets
One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.
Open Targets
One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.
ClinicalTrials.gov
One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.
Cellosaurus
One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.
PubMed and NLM's journal list
One journal with its papers in PubMed since 1959, year by year, its retracted papers, errata and expressions of concern, and how many of its papers have a copy in PMC.
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant